# A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

> **NCT06709040** · — · ENROLLING_BY_INVITATION · sponsor: **Novo Nordisk A/S** · enrollment: 500 (estimated)

## Conditions studied

- Growth Hormone Deficiency
- Neoplasms
- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Somapacitan

## Key facts

- **NCT ID:** NCT06709040
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-12-13
- **Primary completion:** 2034-04-14
- **Final completion:** 2034-04-14
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06709040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06709040, "A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06709040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*